secwatch.observer — SEC 8-K summary
======================================

Issuer:     IR-Med, Inc. (—)
CIK:        0001839133
Form:       8-K
Filed at:   2024-08-28T23:59:59+00:00
Accession:  0001493152-24-034186
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IR-Med appoints Ran Ziskind as CEO effective September 1, 2024
--------------------------------------------------------------

- Ran Ziskind replaces Ronnie Klein, who was interim CEO and remains CTO.
- Ziskind receives 1,400,000 restricted shares at $0.58/share, vesting over 4 years.
- Salary: NIS 6,000/month until $4M funding raised, then NIS 45,000/month plus NIS 10,000 car.
- Ziskind co-founded Galatea Ltd., later acquired by Sarin Technologies; background in electro-optics.
- PressureSafe product ready to launch; pipeline includes other noninvasive diagnostic indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1839133/000149315224034186/0001493152-24-034186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1839133/000149315224034186/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-034186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer